Ignite Creation Date:
2024-05-06 @ 3:26 PM
Last Modification Date:
2024-10-26 @ 1:49 PM
Study NCT ID:
NCT04634409
Status:
COMPLETED
Last Update Posted:
2022-07-01
First Post:
2020-11-17
Brief Title:
A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness
Sponsor:
Eli Lilly and Company
Organization:
Eli Lilly and Company
Study Overview
Official Title:
A Randomized Double-blind Placebo-Controlled Phase 2 Study to Evaluate the Efficacy and Safety of Mono and Combination Therapy With Monoclonal Antibodies in Participants With Mild to Moderate COVID-19 Illness BLAZE-4
Status:
COMPLETED
Status Verified Date:
2022-06
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
BLAZE-4
Brief Summary:
The purpose of this study is to measure how well monoclonal antibodies work either alone or in combination against the virus that causes COVID-19 Study drugs will be given to participants with early symptoms of COVID-19 Samples will be taken from the back of the nose to determine how much virus is in the body at various times during the study Participation could last about 12 or 24 weeks and includes at least 1 visit to the study site with the remainder of assessments performed in the home local clinic or by phone
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None
Secondary IDs
| Secondary ID | Type | Domain | Link |
|---|---|---|---|
| J2X-MC-PYAH | OTHER | Eli Lilly and Company | None |